Emdagan Plus

Emdagan Plus 5/850 Tablets

Empagliflozin

SHAIGAN PHARMACEUTICALS (PVT) LTD.

Drug Identity

Active Ingredient
Empagliflozin
Drug Class
Blood Glucose Lowering Drugs, Excluding Insulin
ATC Code
A10BK03
Status
Essential Medicine

How to Take It

Dosage information not available for this product.

Safety Alerts

Diabetic ketoacidosis, severe hepatic impairment, severe renal impairment, acute conditions predisposing to renal impairment, acute metabolic acidosis or pre-coma, cardiac or respiratory failure, recent MI, alcoholism, pregnancy, lactation, and elderly (above 75yrs)

Important Warnings

Congestive heart failure and cardiovascular disease, hepatic impairment, renal impairment, complicated urinary tract infections
consider temporarily interrupting treatment
Avoid initiation if eGFR below 60 ml/minute/1
Avoid if eGFR is persistently below 45 ml/minute/1
Monitor renal function before starting treatment and regularly during treatment
Monitor electrolyte balance and ensure adequate hydration
Correct hypovolaemia before starting treatment
Consider interrupting treatment if volume depletion occurs, concomitant antihypertensive therapy or use of diuretics

Side Effects

Genital infectionhypoglycaemia (in combination with insulin or sulfonylurea)polyuriapruritusurinary tract infectiondysuriavolume depletion (rare). Reports of altered LFTshepatitisGI upsettaste disturbanceskin reactionsreduced B12 absorptionsabnormal liver function testsrarely lactic acidosis

Drug Interactions

Diuretics
antihypertensive
UGT enzyme inducers
agents affecting renal functions
Alcohol
iodinated contrast agents
diuretics
corticosteroids

Pregnancy & Lactation

Pregnancy
Advised to avoid
Lactation
Advised to avoid

Price Intelligence

Rs 578.33
DRAP approved maximum price · per pack of 14 · approved 24 Sep, 2025
No retail price observed for this pack. Retailers may not exceed the approved maximum.
Prices across sources
No retail prices recorded

Should you consider an alternative?

Other options containing Empagliflozin, and what they are not.

For pharma professionalsCompany, market and opportunity intelligence

Company

Prices as of 30 July 2026 · DRAP ceiling as of 30 July 2026 · schema v3-SKU

For medicine intelligence and professional reference only. Not medical advice.